---
title: "Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286287214.md"
description: "H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Arvinas Holding Company, maintaining a price target of $18. The rating is based on the company's near-term execution and long-term pipeline value, particularly highlighting the VEPPANU licensing deal with Rigel. Fein noted that the U.S. clinical hold on ARV-102 appears procedural, with EU development progressing. He also sees potential in the KRAS and BCL6 programs. Barclays also assigned a Buy rating with a $20 price target."
datetime: "2026-05-13T15:05:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286287214.md)
  - [en](https://longbridge.com/en/news/286287214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286287214.md)
---

# Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company today and set a price target of $18.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Andrew Fein has given his Buy rating due to a combination of factors that highlight both near‑term execution and long‑term pipeline value. He views the VEPPANU licensing deal with Rigel as strategically attractive, since Rigel’s existing oncology infrastructure can support a rapid, efficient launch following early approval, while global rights with future sublicensing preserve additional upside.

Fein also emphasizes that the temporary U.S. clinical hold on ARV‑102 in PSP appears procedural rather than safety‑related, with EU development progressing and offering a potentially swift path to proof‑of‑concept. In parallel, he sees meaningful optionality in the KRAS and BCL6 programs, where a more selective KRAS G12D degrader, favorable immunologic profile, and emerging activity in AITL collectively differentiate Arvinas’s platform, supporting a maintained $18 price target and Buy rating.

In another report released today, Barclays also assigned a Buy rating to the stock with a $20.00 price target.

### Related Stocks

- [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md)
- [RIGL.US](https://longbridge.com/en/quote/RIGL.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [These Analysts Increase Their Forecasts On Arvinas After Q1 Results](https://longbridge.com/en/news/286300592.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Insider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of Stock](https://longbridge.com/en/news/286321834.md)